About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Liver Diseases group is a referent at the local, national and international level in research, and is one of the most active groups in clinical research at VHIR. The group's prominent involvement in clinical trials is a clear indication of our professionals' commitment to ensuring that patients have access to state-of-the-art therapies. Our participation and collaboration in international projects and consortiums are also a fundamental characteristic of the group. The main objective of the group is to become one of the best translational research groups in liver diseases. It is essential to be able to apply all the findings of basic research to clinical research to improve the health of patients with liver disease.
PMID: 37915955 Journal: World Allergy Organization Journal Year: 2023 Reference: World Allergy Organ J. 2023 Oct 20;16(10):100821. doi: 10.1016/j.waojou.2023.100821. eCollection 2023 Oct. Impact factor: Publication type: Paper in international publication Authors: Aixut, Sandra; Ansotegui, Ignacio J; Caminati, Marco; Campbell, Dianne E; Cardona, Victoria; Chiarella, Sergio E; Crego-Vicente, Beatriz; Cuervo-Pardo, Lyda; Darlenski, Razvigor; Ebisawa, Motohiro et al. DOI: 10.1016/j.waojou.2023.100821
PMID: 37916574 Journal: LIVER INTERNATIONAL Year: 2023 Reference: Liver Int. 2023 Nov 2. doi: 10.1111/liv.15776. Impact factor: Publication type: Paper in international publication Authors: Aguilar-Riera, Cristina; Biagetti, Betina; Buti, Maria; Campos-Martorell, Ariadna; Casado, Miguel Angel; Clemente, Maria; Dominguez-Hernandez, Raquel; Esteban, Rafael; Fabregas, Anna; Gonzalez-Llorens, Nuria et al. DOI: 10.1111/liv.15776
PMID: 37921755 Journal: CLINICAL CANCER RESEARCH Year: 2023 Reference: Clin Cancer Res. 2023 Nov 3. doi: 10.1158/1078-0432.CCR-23-1796. Impact factor: Publication type: Paper in international publication Authors: Bardia, Aditya; Bellet-Ezquerra, Meritxell; Bond, John W; Boni, Valentina; Buti, Maria; Casado, Miguel Angel; Chang, Ching-Wei; Dominguez-Hernandez, Raquel; Eng-Wong, Jennifer; Esteban, Rafael et al. DOI: 10.1158/1078-0432.CCR-23-1796
PMID: 37930713 Journal: EUROPEAN HEART JOURNAL Year: 2023 Reference: Eur Heart J. 2023 Oct 31:ehad529. doi: 10.1093/eurheartj/ehad529. Impact factor: Publication type: Paper in international publication Authors: Bes, Marta; Busskamp, Holger; Chan, Henry Lik-Yuen; Esteban, Juan Ignacio; Fernandez-Hidalgo, Nuria; Ferreira-Gonzalez, Ignacio; Kohansal-Nodehi, Mahdokht; Kohler, Bruno; Kroeniger, Konstantin; Piratvisuth, Teerha et al. DOI: 10.1093/eurheartj/ehad529
PMID: 35377229 Journal: Microbiology Spectrum Year: 2022 Reference: Microbiol Spectr. 2022 Apr 27;10(2):e0214921. doi: 10.1128/spectrum.02149-21. Epub 2022 Apr 4. Impact factor: 7.171 Publication type: Paper in international publication Authors: Rodriguez-Frias, Francisco, Buti, Maria, Pumarola, Tomas, Garcia-Garcia, Selene, Cortese, Maria Francesca, Riveiro-Barciela, Mar, Tabernero, David, Rodriguez-Algarra, Francisco, Palom, Adriana, Sopena, Sara et al. DOI: 10.1128/spectrum.02149-21
PMID: 35351135 Journal: BMC Medicine Year: 2022 Reference: BMC Med. 2022 Mar 29;20(1):129. doi: 10.1186/s12916-022-02345-w. Impact factor: 8.775 Publication type: Paper in international publication Authors: Gallo, Monica Martinez, Arrese-Munoz, Iria, Gine, Anna, Diaz-Troyano, Noelia, Gabriel-Medina, Pablo, Riveiro-Barciela, Mar, Labrador-Horrillo, Moises, Martinez-Valle, Fernando, Montalva, Adrian Sanchez, Hernandez-Gonzalez, Manuel et al. DOI: 10.1186/s12916-022-02345-w
PMID: 35337007 Journal: Viruses-Basel Year: 2022 Reference: Viruses. 2022 Mar 14;14(3). pii: v14030600. doi: 10.3390/v14030600. Impact factor: 5.048 Publication type: Review in international publication Authors: Anton, Andres, Quer, Josep, Colomer-Castell, Sergi, Campos, Carolina, Andres, Cristina, Pinana, Maria, Cortese, Maria Francesca, Gonzalez-Sanchez, Alejandra, Garcia-Cehic, Damir, Ibanez, Marta et al. DOI: 10.3390/v14030600
PMID: 35220659 Journal: LIVER INTERNATIONAL Year: 2022 Reference: Liver Int. 2022 May;42(5):1109-1120. doi: 10.1111/liv.15207. Epub 2022 Mar 7. Impact factor: 5.828 Publication type: Paper in international publication Authors: Jimenez, Cesar, Ventura-Cots, Meritxell, Sala, Margarita, Calafat, Margalida, Garcia-Retortillo, Montserrat, Cirera, Isabel, Canete, Nuria, Soriano, German, Poca, Maria, Simon-Talero, Macarena et al. DOI: 10.1111/liv.15207
Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.
The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.
The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.
Des de Vall d'Hebron estem buscant 200 persones voluntàries sanes d'entre 18 i 30 anys per a participar en un estudi sobre els patrons de consum habitual de l'alcohol en població jove, en el marc del projecte StopALD.
